My watch list  


Systematic (IUPAC) name
CAS number 15676-16-1
ATC code N05AL01 N05AL07
PubChem 5355
DrugBank APRD00032
Chemical data
Formula C15H23N3O4S 
Mol. mass 341.427 g/mol
Pharmacokinetic data
Bioavailability 25–35%
Metabolism  ?
Half life 7 hours
Excretion  ?
Therapeutic considerations
Pregnancy cat.


Legal status
Routes  ?

Sulpiride (sold as Meresa, Sulpirid Ratiopharm, Sulpirid Neuraxpharm, Bosnyl, Dogmatil, Eglonyl) is an anti-psychotic drug used mainly in the treatment of psychosis (e.g. schizophrenia) and depression. It is a substituted benzamide. Sulpiride is more commonly used in Europe and Japan. So far it has not been approved in the US and Canada. The drug has strong chemical and clinical similarities to the novel anti-psychotic amisulpride.




Sulpiride is absorbed slowly from the GI-Tract. Its oral bioavailability is only 25 to 35% with marked interindividual differences. The peak plasma concentration is reached 4.5 hours after oral dosing. The usual half-life is 6 to 8 hours. Ninety-two percent is excreted unchanged in the urine. Sulpiride is usually given in 2 or 3 divided doses.

Pharmacodynamic properties

Sulpiride is a selective antagonist at postsynaptic D2-receptors. This action dominates in doses exceeding 600 mg daily. In doses of 600 to 1,600 mg sulpiride shows mild sedating and antipsychotic activity. Its antipsychotic potency compared to chlorpromazine is only 0.2 (1/5). In low doses (in particular 50 to 200 mg daily) its prominent feature is antagonism of presynaptic inhibitory dopamine receptors accounting for some antidepressant activity and a stimulating effect. Therefore, it is in these doses used as a second line antidepressant. Additionally, it alleviates vertigo.

Uses and dosage

  • Productive psychosis: treatment with rather high doses—in excess of 600 mg daily.
  • Long-term Treatment of negative (unproductive) psychosis: in moderate doses (approx. 600 mg daily)
  • Treatment of depression and vertigo: in low to moderate doses (50 to 200 mg daily)

Contraindications and cautions

  • Hypersensitivity to sulpiride
  • Pre-existing breast cancer or other prolactin-dependent tumors
  • Phaeochromocytoma
  • Intoxication with other centrally active drugs
  • Concomitant use of levodopa
  • Caution : Pre-existing Parkinson's Disease
  • Caution : Patients below 18 years of age (insufficient clinical data)
  • Caution : Pre-existing severe heart disease/bradycardia, or hypokalemia (predisposing to long QT syndrome and severe arrhythmias)
  • Caution : Patients with pre-existing epilepsy. Anticonvulsant therapy should be maintained.

Pregnancy and lactation

  • Pregnancy: Animal studies did not reveal any embryo- or fetotoxic properties nor did limited human experience. Due to insufficient human data, pregnant women should be treated with Sulpiride only if strictly indicated. Additionally, the newborns of treated women should be monitored, because isolated cases of extrapyramidal side effects have been reported.
  • Lactation: Sulpiride is found in the milk of lactating women. Since the consequences are unclear, women should not breastfeed during treatment.

Side effects

Sulpiride has fewer extrapyramidal side effects (dystonia, parkinsonism, tardive dyskinesia and akathisia) than many of the older antipsychotic medications. Most of these do not seem to occur in a dose related manner. Other side effects occur infrequently (hypotension, rarely long-QT syndrome, dry mouth, sweating, nausea, activation or sedation, insomnia, allergic rash or pruritus). Isolated cases of the potentially life-threatening NMS (neuroleptic malignant syndrome) have been reported. Sulpiride should not be taken after 4 p.m. in order to avoid insomnia. The foremost problem with sulpiride is a strong stimulation of prolactin-secretion; whether this may contribute to the development of breast-cancer in women is currently not known.

  • Levodopa : Sulpiride and levodopa have antagonistic effects.
  • Alcohol : Sedation and hypotension may be potentiated.
  • Antihypertensive agents : Hypotension may be potentiated (risk of postural collapse).
  • Other central depressants : Increased sedation with negative impact on the capacity to drive or operate machinery.


Sulpiride has a relatively low order of acute toxicity. Substantial amounts may cause severe but reversible dystonic crises with torticollis, protrusion of the tongue, and/or trism. In some cases all the classical symptoms typical of severe Parkinson's Disease may be noted; in others, over-sedation/coma may occur. The treatment is largely symptomatic. Some or all extrapyramidal reactions may respond to the application of anticholinergic drugs such as Biperiden or Benztropine. All patients should be closely monitored for signs of long-QT syndrome and severe arrhythmias.

GHB receptor

The benzamide neuroleptics (including amisulpride and sulpiride) have been shown to activate the endogenous gamma-hydroxybutryate receptor in vivo at theraputic concentrations.[1] GHB has neuroleptic properties and it is believed binding to this receptor may contribute to the effects of these neuroleptics.


  • British National Formulary, 2005
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Sulpiride". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE